These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

843 related articles for article (PubMed ID: 16330718)

  • 1. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis.
    Kemmler G; Hummer M; Widschwendter C; Fleischhacker WW
    Arch Gen Psychiatry; 2005 Dec; 62(12):1305-12. PubMed ID: 16330718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Placebo or active control trials of antipsychotic drugs?
    Fleischhacker WW; Czobor P; Hummer M; Kemmler G; Kohnen R; Volavka J
    Arch Gen Psychiatry; 2003 May; 60(5):458-64. PubMed ID: 12742866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The risk of death among adult participants in trials of antipsychotic drugs in schizophrenia.
    Isaac M; Koch A
    Eur Neuropsychopharmacol; 2010 Mar; 20(3):139-45. PubMed ID: 20053539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Augmentation of clozapine with a second antipsychotic--a meta-analysis of randomized, placebo-controlled studies.
    Taylor DM; Smith L
    Acta Psychiatr Scand; 2009 Jun; 119(6):419-25. PubMed ID: 19245679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses.
    Sinyor M; Levitt AJ; Cheung AH; Schaffer A; Kiss A; Dowlati Y; Lanctôt KL
    J Clin Psychiatry; 2010 Mar; 71(3):270-9. PubMed ID: 20122371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selection of atypical antipsychotics for the management of schizophrenia.
    Sprague DA; Loewen PS; Raymond CB
    Ann Pharmacother; 2004 Feb; 38(2):313-9. PubMed ID: 14742771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features.
    Rabinowitz J; Levine SZ; Barkai O; Davidov O
    Schizophr Bull; 2009 Jul; 35(4):775-88. PubMed ID: 18303093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of "atypical" antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder.
    Lerner V; Libov I; Kotler M; Strous RD
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):89-98. PubMed ID: 14687862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relapse prevention in schizophrenia: evidence from longterm, randomized, double-blind clinical trials.
    Pecenak J
    Neuro Endocrinol Lett; 2007 Feb; 28 Suppl 1():49-70. PubMed ID: 17262007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2012 Jun; 73(6):856-64. PubMed ID: 22687813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
    Houthoofd SA; Morrens M; Sabbe BG
    Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons.
    Fraguas D; Correll CU; Merchán-Naranjo J; Rapado-Castro M; Parellada M; Moreno C; Arango C
    Eur Neuropsychopharmacol; 2011 Aug; 21(8):621-45. PubMed ID: 20702068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A controlled, mirror-image study of second-generation antipsychotics in the treatment of schizophrenia.
    Taylor D; Hayhurst K; Kerwin R
    Int Clin Psychopharmacol; 2007 May; 22(3):133-6. PubMed ID: 17414738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moderators of placebo response to antipsychotic treatment in patients with schizophrenia: a meta-regression.
    Welge JA; Keck PE
    Psychopharmacology (Berl); 2003 Feb; 166(1):1-10. PubMed ID: 12494247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
    Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
    Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of life in the long-term treatment and the role of second-generation antipsychotics.
    Mohr P
    Neuro Endocrinol Lett; 2007 Feb; 28 Suppl 1():117-33. PubMed ID: 17262004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are there any differences in the efficacy among second generation antipsychotics in the treatment of schizophrenia and related disorders?
    Motlová L; Spaniel F; Höschl C; Balon R
    Ann Clin Psychiatry; 2007; 19(2):133-43. PubMed ID: 17612853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials.
    Weiden PJ; Cutler AJ; Polymeropoulos MH; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S12-9. PubMed ID: 18334908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.